Goldman Sachs–affiliated entities reported multiple transactions in Attovia Therapeutics common stock and preferred stock. On completion of Attovia’s IPO, all redeemable convertible preferred stock automatically converted into common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split, and prior Form 3 conversion figures were corrected. GS&Co, acting as a market maker, bought 85,000 shares and sold 105,807 shares of common stock on August 5, 2026, and additional common shares were purchased in the IPO by affiliated investment vehicles.
Deep Track Capital and affiliates report a significant ownership position in Attovia Therapeutics, Inc. The group, consisting of Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reports beneficial ownership of 3,207,138 shares of Attovia common stock, representing 7.45% of the outstanding class. The reporting persons have shared voting and dispositive power over all 3,207,138 shares and no sole voting or dispositive power. The ownership percentage is based on 43,029,017 shares of common stock outstanding as of August 5, 2026, as referenced from Attovia’s prospectus. David Kroin may be considered a control person of Deep Track Capital, LP, and the parties have filed a joint statement reflecting their coordinated reporting.
Attovia Therapeutics, Inc. received a large shareholder disclosure from several Frazier Life Sciences funds. Frazier Life Sciences Public Fund, L.P. reports beneficial ownership of 760,327 shares of common stock, or 1.7% of the class, based on 45,579,017 shares anticipated to be outstanding after the IPO. Frazier Life Sciences XI, L.P. reports 6,154,213 shares, or 13.5%, and Frazier Life Sciences XII, L.P. reports 54,163 shares, or 0.1%.
FLS XI acquired its position primarily through pre-IPO preferred stock and common stock purchases totaling about $59,979,760, which converted into common stock at the IPO, while FLSPF, FLS XI and FLS XII bought additional IPO shares at $17.00 per share for an aggregate $21,250,000. FLSPF and FLS XII then made follow-on open-market purchases on August 5–7, 2026 within stated price ranges.
The holdings are described as for investment purposes, with no current plans for corporate control actions. Certain Frazier funds are subject to 180‑day lock-up agreements after the IPO prospectus date and benefit from an Amended and Restated Investors' Rights Agreement providing registration rights for resales, subject to customary limitations.
Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering. 18,181,818 preferred shares converted into 1,957,138 common shares at a 9.29-for-one ratio, resulting in 1,957,138 common shares held directly. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but each disclaims beneficial ownership beyond their respective pecuniary interests.
venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, Inc., reported multiple equity transactions tied to Attovia’s initial public offering. On August 6, 2026, the fund converted 21,477,273 Series A, 7,636,362 Series B, and 6,179,219 Series C Preferred Stock shares into Common Stock as part of an automatic conversion at IPO, as adjusted for a 1-for-9.29 reverse stock split effective July 29, 2026. The filing also reports an additional open-market purchase of 382,352 Common Stock shares at $17.00 per share. These securities are held directly by venBio Global Strategic Fund IV, L.P.; its general partner entities and members disclaim beneficial ownership beyond their pecuniary interest.
Attovia Therapeutics, Inc. reported insider activity by investment entities associated with Redmile Group and Jeremy Green as ten percent owners. On August 6, 2026, 782,854 shares of Series B Preferred Stock automatically converted in full into the same number of common shares upon completion of Attovia’s IPO for no consideration. On the same date, Redmile-managed vehicles purchased an additional 600,000 shares of common stock at $17.00 per share in the IPO, including a 200,000-share direct purchase that brought one reported direct common position to 982,854 shares. The filing notes that Redmile and Jeremy Green may be deemed beneficial owners through their roles as manager and principal, while disclaiming beneficial ownership beyond any pecuniary interest.
Frazier Life Sciences XI, L.P., together with affiliated general partners FHMLS XI, L.P. and FHMLS XI, L.L.C., reported multiple conversions of preferred stock in Attovia Therapeutics, Inc. On August 6, 2026, Series A‑1, A‑2, B and C Preferred Stock automatically converted into Common Stock on a 9.29:1 basis immediately upon closing of Attovia’s initial public offering, eliminating these preferred positions. In connection with these automatic conversions, Frazier received blocks of Attovia Common Stock, all held directly by Frazier Life Sciences XI, L.P. In a separate transaction the same day, Frazier purchased 588,235 shares of Attovia Common Stock at $17.00 per share in an open‑market or private transaction, increasing its Common Stock holdings; post‑transaction Common Stock balances are not specified in this report.
Attovia Therapeutics director Angie You received a grant of stock options for 27,000 shares of common stock. The options have an exercise price of $17.00 per share and expire on August 3, 2036. According to the terms, the options vest in full on the earlier of August 4, 2027 or the next annual stockholders’ meeting, subject to continued service. Following this grant, the reported derivative holdings from this award total 27,000 options held directly.
Attovia Therapeutics, Inc. reported that director Mitchell Gold received a grant of 27,000 stock options to buy common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the award terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service.
Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026. The options carry a $17.00 per share exercise price and expire on August 3, 2036. 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, she holds 140,000 stock options directly.